Request Demo
Last update 07 Jun 2025
VAK-694
Last update 07 Jun 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms NVP-VAK-694, NVP-VAK694, VAK 694 + [1] |
Target |
Action inhibitors |
Mechanism IL-4 inhibitors(Interleukin-4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with VAK-694NCT01568762
A Randomized, Double-blind, Placebo Controlled Study to Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 (Sequential Administration of a Fixed Dose of VAK694 and Single Ascending Doses of QAX576) in Patients With Well-controlled Mild to Moderate Asthma
NCT01018693
Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis
NCT00929968
A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen
100 Clinical Results associated with VAK-694
Login to view more data
100 Translational Medicine associated with VAK-694
Login to view more data
100 Patents (Medical) associated with VAK-694
Login to view more data
100 Deals associated with VAK-694
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rhinitis, Allergic, Seasonal | Phase 2 | United Kingdom | 01 Nov 2009 | |
| Seasonal rhinitis | Phase 2 | United States | 01 Jun 2009 | |
| Seasonal rhinitis | Phase 2 | Canada | 01 Jun 2009 | |
| Allergic asthma | Phase 1 | United States | 01 Oct 2010 | |
| Rhinitis, Allergic | Phase 1 | United States | 01 Oct 2007 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free